Menu Search
Equities

Vivani Medical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
U5P:DUS

Vivani Medical Inc

Actions
  • Price (EUR)1.03
  • Today's Change0.04 / 4.04%
  • Shares traded--
  • 1 Year change-5.50%
  • Beta3.1704
Data delayed at least 15 minutes, as of Feb 17 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

  • Revenue in USD (TTM)0.00
  • Net income in USD-26.03m
  • Incorporated2023
  • Employees42.00
  • Location
    Vivani Medical Inc1350 S. Loop RoadALAMEDA 94502United StatesUSA
  • Phone+1 (415) 506-8462
  • Websitehttps://vivani.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.